Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022. Fitzpatrick, M. C., Laufer, R. S., Baral, R., Driscoll, A. J., Feikin, D. R., Fleming, J. A., Jit, M., Kim, S., Koltai, M., Li, Y., Li, X., Nair, H., Neuzil, K. M., Pecenka, C., Sparrow, E., Srikantiah, P., & Ortiz, J. R. Vaccine, 41(48):7047–7059, November, 2023. doi abstract bibtex Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.
@article{fitzpatrick_report_2023,
title = {Report of the {WHO} technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, {April} 7-8, 2022},
volume = {41},
issn = {1873-2518},
doi = {10.1016/j.vaccine.2023.09.040},
abstract = {Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.},
language = {eng},
number = {48},
journal = {Vaccine},
author = {Fitzpatrick, Meagan C. and Laufer, Rachel S. and Baral, Ranju and Driscoll, Amanda J. and Feikin, Daniel R. and Fleming, Jessica A. and Jit, Mark and Kim, Sonnie and Koltai, Mihaly and Li, You and Li, Xiao and Nair, Harish and Neuzil, Kathleen M. and Pecenka, Clint and Sparrow, Erin and Srikantiah, Padmini and Ortiz, Justin R.},
month = nov,
year = {2023},
pmid = {37777450},
pmcid = {PMC10680976},
keywords = {Humans, Infant, Respiratory Syncytial Virus Infections, Developing Countries, Cost-Effectiveness Analysis, Respiratory Syncytial Virus, Human, Cost-Benefit Analysis, Referral and Consultation, Hospitalization, World Health Organization, Cost effectiveness, Global health, Monoclonal antibody, Respiratory syncytial virus, Vaccine},
pages = {7047--7059},
}
Downloads: 0
{"_id":"2nQBCcP3rPKrSvRmp","bibbaseid":"fitzpatrick-laufer-baral-driscoll-feikin-fleming-jit-kim-etal-reportofthewhotechnicalconsultationontheevaluationofrespiratorysyncytialviruspreventioncosteffectivenessinlowandmiddleincomecountriesapril782022-2023","author_short":["Fitzpatrick, M. C.","Laufer, R. S.","Baral, R.","Driscoll, A. J.","Feikin, D. R.","Fleming, J. A.","Jit, M.","Kim, S.","Koltai, M.","Li, Y.","Li, X.","Nair, H.","Neuzil, K. M.","Pecenka, C.","Sparrow, E.","Srikantiah, P.","Ortiz, J. R."],"bibdata":{"bibtype":"article","type":"article","title":"Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022","volume":"41","issn":"1873-2518","doi":"10.1016/j.vaccine.2023.09.040","abstract":"Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.","language":"eng","number":"48","journal":"Vaccine","author":[{"propositions":[],"lastnames":["Fitzpatrick"],"firstnames":["Meagan","C."],"suffixes":[]},{"propositions":[],"lastnames":["Laufer"],"firstnames":["Rachel","S."],"suffixes":[]},{"propositions":[],"lastnames":["Baral"],"firstnames":["Ranju"],"suffixes":[]},{"propositions":[],"lastnames":["Driscoll"],"firstnames":["Amanda","J."],"suffixes":[]},{"propositions":[],"lastnames":["Feikin"],"firstnames":["Daniel","R."],"suffixes":[]},{"propositions":[],"lastnames":["Fleming"],"firstnames":["Jessica","A."],"suffixes":[]},{"propositions":[],"lastnames":["Jit"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Kim"],"firstnames":["Sonnie"],"suffixes":[]},{"propositions":[],"lastnames":["Koltai"],"firstnames":["Mihaly"],"suffixes":[]},{"propositions":[],"lastnames":["Li"],"firstnames":["You"],"suffixes":[]},{"propositions":[],"lastnames":["Li"],"firstnames":["Xiao"],"suffixes":[]},{"propositions":[],"lastnames":["Nair"],"firstnames":["Harish"],"suffixes":[]},{"propositions":[],"lastnames":["Neuzil"],"firstnames":["Kathleen","M."],"suffixes":[]},{"propositions":[],"lastnames":["Pecenka"],"firstnames":["Clint"],"suffixes":[]},{"propositions":[],"lastnames":["Sparrow"],"firstnames":["Erin"],"suffixes":[]},{"propositions":[],"lastnames":["Srikantiah"],"firstnames":["Padmini"],"suffixes":[]},{"propositions":[],"lastnames":["Ortiz"],"firstnames":["Justin","R."],"suffixes":[]}],"month":"November","year":"2023","pmid":"37777450","pmcid":"PMC10680976","keywords":"Humans, Infant, Respiratory Syncytial Virus Infections, Developing Countries, Cost-Effectiveness Analysis, Respiratory Syncytial Virus, Human, Cost-Benefit Analysis, Referral and Consultation, Hospitalization, World Health Organization, Cost effectiveness, Global health, Monoclonal antibody, Respiratory syncytial virus, Vaccine","pages":"7047–7059","bibtex":"@article{fitzpatrick_report_2023,\n\ttitle = {Report of the {WHO} technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, {April} 7-8, 2022},\n\tvolume = {41},\n\tissn = {1873-2518},\n\tdoi = {10.1016/j.vaccine.2023.09.040},\n\tabstract = {Policymakers often rely on impact and cost-effectiveness evaluations to inform decisions about the introduction of health interventions in low- and middle-income countries (LMICs); however, cost-effectiveness results for the same health intervention can differ by the choice of parameter inputs, modelling assumptions, and geography. Anticipating the near-term availability of new respiratory syncytial virus (RSV) prevention products, WHO convened a two-day virtual consultation in April 2022 with stakeholder groups and global experts in health economics, epidemiology, and vaccine implementation. The objective was to review methods, parameterization, and results of existing cost-effectiveness analyses for RSV prevention in LMICs; identify the most influential inputs and data limitations; and recommend and prioritize future data gathering and research to improve RSV prevention impact estimates in LMICs. Epidemiological parameters identified as both influential and uncertain were those associated with RSV hospitalization and death, specifically setting-specific hospitalization rates and RSV-attributable death rates. Influential economic parameters included product price, delivery costs, willingness-to-pay for health on the part of potential donors, and the cost of RSV-associated hospitalization. Some of the influential parameters identified at this meeting should be more precisely measured by further research. Other influential economic parameters that are highly uncertain may not be resolved, and it is appropriate to use sensitivity analyses to explore these within cost-effectiveness evaluations. This report highlights the presentations and major discussions of the meeting.},\n\tlanguage = {eng},\n\tnumber = {48},\n\tjournal = {Vaccine},\n\tauthor = {Fitzpatrick, Meagan C. and Laufer, Rachel S. and Baral, Ranju and Driscoll, Amanda J. and Feikin, Daniel R. and Fleming, Jessica A. and Jit, Mark and Kim, Sonnie and Koltai, Mihaly and Li, You and Li, Xiao and Nair, Harish and Neuzil, Kathleen M. and Pecenka, Clint and Sparrow, Erin and Srikantiah, Padmini and Ortiz, Justin R.},\n\tmonth = nov,\n\tyear = {2023},\n\tpmid = {37777450},\n\tpmcid = {PMC10680976},\n\tkeywords = {Humans, Infant, Respiratory Syncytial Virus Infections, Developing Countries, Cost-Effectiveness Analysis, Respiratory Syncytial Virus, Human, Cost-Benefit Analysis, Referral and Consultation, Hospitalization, World Health Organization, Cost effectiveness, Global health, Monoclonal antibody, Respiratory syncytial virus, Vaccine},\n\tpages = {7047--7059},\n}\n\n","author_short":["Fitzpatrick, M. C.","Laufer, R. S.","Baral, R.","Driscoll, A. J.","Feikin, D. R.","Fleming, J. A.","Jit, M.","Kim, S.","Koltai, M.","Li, Y.","Li, X.","Nair, H.","Neuzil, K. M.","Pecenka, C.","Sparrow, E.","Srikantiah, P.","Ortiz, J. R."],"key":"fitzpatrick_report_2023","id":"fitzpatrick_report_2023","bibbaseid":"fitzpatrick-laufer-baral-driscoll-feikin-fleming-jit-kim-etal-reportofthewhotechnicalconsultationontheevaluationofrespiratorysyncytialviruspreventioncosteffectivenessinlowandmiddleincomecountriesapril782022-2023","role":"author","urls":{},"keyword":["Humans","Infant","Respiratory Syncytial Virus Infections","Developing Countries","Cost-Effectiveness Analysis","Respiratory Syncytial Virus","Human","Cost-Benefit Analysis","Referral and Consultation","Hospitalization","World Health Organization","Cost effectiveness","Global health","Monoclonal antibody","Respiratory syncytial virus","Vaccine"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://leoly2017.github.io/group/citations.bib","dataSources":["acjQJrDfd43dtXDph"],"keywords":["humans","infant","respiratory syncytial virus infections","developing countries","cost-effectiveness analysis","respiratory syncytial virus","human","cost-benefit analysis","referral and consultation","hospitalization","world health organization","cost effectiveness","global health","monoclonal antibody","respiratory syncytial virus","vaccine"],"search_terms":["report","technical","consultation","evaluation","respiratory","syncytial","virus","prevention","cost","effectiveness","low","middle","income","countries","april","2022","fitzpatrick","laufer","baral","driscoll","feikin","fleming","jit","kim","koltai","li","li","nair","neuzil","pecenka","sparrow","srikantiah","ortiz"],"title":"Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022","year":2023}